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Summary 
Renal transplant recipients (RTRs) patients are at increased risk of car-
diovascular morbidity and mortality. We aimed this study to assess re-
ticulated platelets (RP), platelet reactivity and von Willebrand factor 
(vWF) levels in RTRs patients. In 150 RTRs patients [84 (56%) not on 
acetylsalicylic acid (ASA) treatment, group A; 66 (44%) on ASA 100 mg 
treatment, group B] and in 60 healthy control subjects, RP were 
measured by a Sysmex XE-2100 and were expressed as the percentage 
of RP of the total optical platelet count (immature platelet fraction; IPF), 
as the percentage of RP highly fluorescent (H-IPF) and as the absolute 
number of RP (IPF#). Platelet function was assessed by optical aggrego-
metry (PA) induced by 1 mmol arachidonic acid (AA-PA), 2 and 10 μM 
ADP (ADP2-PA and ADP10-PA) and 2 μg/ml collagen (Coll-PA). vWF lev-
els were measured by using a miniVidas analyser. Group A and group B 
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showed significant higher values of RP than controls. At a multiple lin-
ear regression analysis IPF and IPF# were significantly and positively re-
lated to collagen-PA. By analysing group B according to residual pla-
telet reactivity (RPR), we observed a significant higher number of RP 
among patients with RPR by collagen. Moreover at a multiple logistic 
regression analysis, IPF# significantly affected the risk of having a RPR 
by collagen. With regard to vWF, RTRs patients showed higher levels 
than control subjects. We documented a higher platelet turn-over in 
both groups of RTRs patients and increased platelet reactivity in RTRs 
patients not on ASA therapy than controls.  
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Introduction 
Despite great improvement in patient and graft survival, the long-
term morbidity and mortality in renal transplant recipients 
(RTRs) are still significant, with a high incidence of cardiovascular 
disease-related deaths compared with age-matched control popu-
lations (1). A number of studies have shown the importance of 
some classical risk factors such as hyperlipidaemia and hyperten-
sion in determining cardiovascular disease in RTRs patients, but 
the presence of risk factors is not able to completely predict the pa-
tient survival (2–3). Various mechanisms can be responsible for 
the cardiovascular complications in RTRs patients. Disturbances 
in haemostasis and endothelial dysfunction are common compli-
cations of kidney disease, as RTRs patients show an increase of the 
endothelial cell injury and an activation of coagulation with re-
spect to healthy subjects (4–7). von Willebrand factor (vWF), a 
multimeric protein which regulates platelet adhesion to the sub-
endothelium, may give a good indication of the grade of endothe-
lial perturbation showing a significant increase among RTRs pa-
tients with respect to healthy controls (6). Moreover, platelets from 
RTRs patients showed an enhanced thromboxane biosynthesis (6) 
and some immunosuppressive agents commonly used in RTRs pa-
tients such as cyclosporine have been found to be associated with 
increased platelet procoagulant activity (8–9). 
To date, epidemiological studies demonstrated that low-dose 
ASA therapy can substantially improve renal allograft function 
and survival so reducing the incidence of cardiovascular compli-
cations in RTRs patients (10). Nevertheless, it has been recently re-
ported that the magnitude of antiplatelet effects may be depressed 
in RTRs patients by the presence of an “aspirin resistance” 
measured by a point-of-care method (11). The presence of an en-
hanced platelet turnover, as documented by high levels of reticu-
lated platelets (RP) expressed as immature platelet fraction (IPF), 
was initially reported in populations of patients with idiopathic 
thrombocytopenic purpura (ITP) (12–13). 
Recently we demonstrated a high rate of platelet turnover as a 
new mechanism associated with enhanced platelet reactivity in 
high risk coronary artery disease (CAD) patients on dual antipla-
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telet therapy (14). However, to the best of our knowledge data on 
the presence of RP with particular regard to platelet reactivity and 
endothelial dysfunction in RTRs patients are not available. Hence, 
aim of this study was to contemporary assess, in a population of 
RTRs patients treated or not with acetylsalicylic acid (ASA) and in 
a population of healthy controls, reticulated platelets, vWF and 
platelet aggregation.  
Methods  
Study population 
The study population comprised 150 RTRs patients (98male, 52 fe-
male) followed according to American Society of Nephrology 
guidelines (15) with a median age of 50 (17–75) years [group A: 
84/150 (56%) not on ASA treatment: group B: 66/150 (44%) on 
ASA treatment] admitted to the Renal Unit of the Azienda Ospeda-
liero-Universitaria Careggi at least six months after the renal trans-
plantation. There was no clinical evidence of acute renal graft re-
jection or proteinuria higher than 1g/24 hours. At the time of the 
venous blood withdrawal the presence of cytomegalovirus 
(CMV)-viraemia was investigated using a semiquantitative PCR 
assay on peripheral blood. There was no clinical or laboratory evi-
dence of acute CMV infection in any patient.  
The control population consisted of 60 (41 male, 19 female) 
healthy subjects with a median age of 52 (21–72) years free from 
vascular and renal disease selected to be comparable for age and 
gender with the patients. At the time of blood collection controls 
were free from the use of ASA or anti-inflammatory agents known 
to influence platelet function at least from two weeks. In RTRs pa-
tients, ASA treatment was given to patients with previous vascular 
events or in the presence of a documented peripheral vascular dis-
ease and/or a renal artery stenosis treated with percutaneous an-
gioplasty and stenting and to patients with the concomitant pres-
ence of more than one cardiovascular risk factor. 
Current smoking status was determined at the time of blood 
collection. The subjects were classified as having hypertension ac-
cording to the guidelines of European Society of Hypertension/
European Society of Cardiology (16) or if they reported taking 
antihypertensive medications, as verified by the physician. Dia-
betic subjects were defined in agreement with the American Dia-
betes Association or on the basis of self-report data (if confirmed 
by medication or chart review) (17). Dyslipidaemia was defined 
according to the Third report of the National Cholesterol Edu-
cation Program (NCEP-III) or if they reported taking anti-dyslipi-
daemic drugs, as verified by the physician (18). A positive family 
history was defined as the presence of at least one first-degree 
relative who had developed CAD before the age of 55 years for men 
and 65 years for women. All subjects gave informed consent; the 
study complies with the Declaration of Helsinki and was approved 
by the local ethic committee.  
Blood collection 
Venous blood samples anticoagulated by 0.129 M sodium citrate 
for platelet aggregometry and determination of vWF antigen levels 
(vWF:Ag) and by EDTA 0.17 M for the evaluation of RP were taken 
from each patients in the morning, after an overnight fasting.  
For vWF:Ag determination, whole blood was immediately cen-
trifuged at 3,000 x g at 4°C for 10 minutes (min) and samples were 
frozen at –80°C until analysis. 
Light transmission aggregometry 
Turbidimetric platelet aggregation was used to measure agonist-
induced platelet aggregation. Whole blood samples were centri-
fuged for 10 min at 250 x g to obtain platelet-rich plasma (PRP). 
Platelet-poor plasma (PPP) was obtained on the remaining speci-
men by further centrifugation at 3,000 x g for 3 min. A platelet 
count was measured on the PRP and was adjusted between 180 
x103/μl and 300 x103/μl with PPP. PRP was stimulated with 2 and 
10 μM adenosine diphosphate (ADP) (Milan, Italy), with 1 mmol 
arachidonic acid (AA) (Sigma-Aldrich, Milan, Italy) and with 2 μg/
ml collagen (Mascia Brunelli, Milan, Italy) using a APACT 4 aggre-
gometer (Helena Laboratories Italia S.P.A, Milan, Italy).  
Platelet aggregation (PA) according to Born’s method was 
evaluated considering the maximal percentage of platelet aggre-
gation in response to different stimuli (ADP2-PA, ADP10-PA, 
Coll-PA and AA-PA) after 10 min. The intra-assay coefficients of 
variations (CV) were 4.7% for ADP-PA, 4.4% for AA-PA, and 2.3% 
for Collagen-PA [19].  
We defined patients with residual platelet reactivity (RPR) 
those with platelet aggregation by AA ≥20% and /or Collagen 
≥56% according to the literature (20) and studies from our group 
(21, 22). 
Reticulated platelets 
Reticulated platelets were measured as previously described (14) 
by using the Sysmex XE-2100 haematology analyser (Sysmex, 
Kobe, Japan). RP were expressed as a percentage of RP of the total 
optical platelet count (immature platelet fraction; IPF), as the per-
centage of RP highly fluorescent (H-IPF) and as the absolute 
number of RP (IPF#). The intra-assay CV for IPF, H-IPF and IPF# 
were 10.6%, 18.8% and 10.9% respectively (14). 
VWF:Ag levels 
VWF:Ag was measured by using a miniVidas analyser (BioMe-
rieux, Lyon, France) by following manufacturer’s instructions. The 
intra- and inter-assay CV are 3.4 % and 7.7%, respectively. 
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Statistical analysis 
Statistical analysis was performed using the SPSS (Statistical Pack-
age for Social Sciences, Chicago, IL, USA) software for Windows 
(Version 13.0). Values are presented as median and range.  
The Mann-Whitney test for unpaired data was used for com-
parison between two groups, while the Kruskal-Wallis test for un-
paired data was used for comparison among different groups. A 
correlation analysis for non-parametric data (Spearman’s Test) 
was performed to establish relationships between IPF, H-IPF, IPF#, 
agonist-induced platelet aggregation and vWF. After logarithmic 
transformation, a multivariate linear regression model adjusted 
for cardiovascular risk factors, previous myocardial infarction, 
haematocrit, platelet count, ASA, cyclosporine, rapamycin, my-
cophenolate, tacrolimus, azathioprine and erythropoietin treat-
ment, and glomerular filtration rate (GFR) was used to test the in-
dependent associations of RP with platelet reactivity. P<0.05 was 
considered to be statistically significant.  
Post-hoc sample size calculation indicated that the number of 
84 RTRs patients not on ASA treatment and of 60 controls subjects 
has a sufficient statistical power (Beta=0.80) to detect a significant 
difference in platelet aggregation, with an alpha coefficient of 0.05. 
Results 
Reticulated platelets and platelet aggregation 
Demographic, clinical, and laboratory characteristics of the study 
population are presented in Table 1.  
Gender was significantly related to the IPF# parameter; females 
had significantly higher levels of RP than males [median (range): 
IPF#: 8300 (3500–20200) vs. 6850 (1700–22900) platelets/μl, 
p=0.007].  
RP were positively related with mean platelet volume (MPV) 
[IPF and MPV r =0.58 p<0.0001; H-IPF and MPV r=0.59 
p<0.0001; IPF# and MPV r=0.66 p<0.0001] and negatively related 
with platelet count [ IPF and platelet count r=-0.18 p=0. 03; H-IPF 
and platelet count r=-0.27 p=0.001]. 
By analysing RP values in the three groups, group A showed sig-
nificant higher values of RP with respect to group B and with re-
spect to controls. Group B showed a significant higher percentage 
of RP with respect to control subjects (Fig. 1). 
Notably, a significant difference in platelet aggregation induced 
by all agonists between group A and controls was observed 
(Table 2). Among cardiovascular risk factors, only hypertension 
significantly affected AA-PA in group A [median (range): AA-PA 
90 (10–100) vs. 85 (19–93) p=0.04]. 
In the whole patient population, significant positive cor-
relations between reticulated platelets and PA induced by collagen, 
AA and ADP were found [IPF and Coll-PA: r=0.28, p=0.001; 
H-IPF and Coll-PA: r=0.26, p=0.001, IPF# and Coll-PA: r= 0.22, 
p=0.007; IPF and AA-PA: r=0.22, p=0.009; H-IPF and AA-PA: 
r=0.17, p=0.04; ADP2-PA and IPF: r=0.18, p=0.028; ADP10-PA 
and IPF: r=0.16, p=0.04 ].  
In order to evaluate the influence of reticulated platelets on pla-
telet aggregation we performed a linear regression analysis. At the 
univariate model IPF was significantly and positively related with 
platelet aggregation by AA [β ± SE: lnAA and lnIPF 0.44 ± 0.17, 
p=0.01] but at the multivariate model after adjusting for age, 
gender, hypertension, dyslipidaemia, diabetes, smoking habit, pre-
vious myocardial infarction, haematocrit, platelet count, ASA, 
cyclosporine, rapamycin, mycophenolate, tacrolimus, azathio-
prine and erythropoietin treatment and GFR this association lost 
its significance.  
As regarding RP and collagen-induced platelet aggregation, at 
the univariate model IPF, H-IPH and IPF# were positively and sig-
nificantly related with Coll-PA (Table 3). At a multiple linear re-
gression analysis adjusted for all the confounding factors these as-
sociations remained significant for IPF and IPF# (Table 3).  
In patients on ASA, RPR by collagen was observed in 39/66 
(59.0%) while RPR by AA was observed in 22/66 (33.3%). 
Furthermore, by analysing the group B patients according to the 
presence or not of RPR, we observed a significant higher number 
of RP in patients with RPR by collagen (Table 4). 
At a logistic regression analysis IPF and IPF# significantly af-
fected the risk of having a RPR by collagen at the univariate [odds 
ratio [OR] (95% confidence interval [CI]): Coll and IPF 1.74 
(1.13–2.68) p=0.01; Coll and IPF# 4.07 (1.26–13.08) p=0.02] and 
at the multivariate model [OR (95%CI): Coll and IPF# 4.70 
(1.03–21.39) p=0.04]. 
Relationship between von Willebrand factor,  
reticulated platelets and platelet aggregation 
RTRs patients showed higher levels of vWF with respect to the con-
trol population [vWF:Ag: 195 (71–333)% vs. 108 (70–180)% 
p<0.0001]. 
A significant difference in vWF factor levels was showed be-
tween group A and group B patients [vWF:Ag: 208 (82–311)% vs. 
175 (71–333)% p=0.003] and between group B and control sub-
jects [vWF:Ag: 175 (71–333)% vs. 108 (70–180)% p<0.0001]. 
Moreover, a significant positive correlations were present between 
vWF:Ag and reticulated platelets [IPF and vWF:Ag r=0.27 
p=0.001; H-IPF and vWF:Ag r=0.20 p=0.016] and between 
vWF:Ag and AA-PA and Coll-PA [AA-PA and vWF:Ag r=0.26 
p=0.002; Coll-PA and vWF:Ag r=0.24 p=0.003] in the whole pa-
tients population.  
Moreover, by analysing the group B patients according to the 
presence or not of RPR, we observed higher albeit not significant 
levels of vWF:Ag in patients with RPR by both AA and collagen 
[RPR by AA 190(71–274) % vs. 164 (71–333)% p=0.35; RPR by 
collagen 186 (101–333)% vs. 164 (71–274) % p=0.084]. 
Discussion  
This paper provides new information about the presence of a high 
platelet turn-over in RTRs patients and increased platelet reactivity 
in RTRs patients not on anti-aggregating therapy and the relation-
ship between this hyperreactive state and the presence of RP. In ad-
dition, RTRs patients not on ASA therapy showed significantly 
higher levels of vWF with respect to RTRs patients on ASA therapy, 
and a positive relationship was observed between RP, platelet ag-
gregation by AA and collagen and vWF levels.  
Cardiovascular disease is the major cause of death among RTRs 
and various factors can contribute to induce its susceptibility (23, 
24). The presence of cardiovascular risk factors, infections, and di-
rect effects of immunosuppressive agents are able to induce en-
dothelial cells activation (25, 26) with an up-regulation of en-
dothelial adhesion molecules and subsequent adhesion and acti-
vation of platelets and leukocytes (27, 28). In our study, among car-
diovascular risk factors, hypertension is significantly related to the 
presence of an increased platelet reactivity induced by AA. In hy-
pertensive patients, a reduction of nitric oxide synthetase (NOS) 
activity associated with an activation of platelet aggregability has 
been documented (29) and it is likely that diminished NO bioa-
vailability contributes to an increase platelet activation (30). Inter-
estingly, the presence of diabetes did not influence RP, platelet ag-
gregation or vWF:Ag. This effect is probably due to the low 
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Table 1: Demographic, clinical and labora-
tory characteristics of the study popu-
lation. *Values are expressed as median and 
range. DVT, deep-vein thrombosis; CHD, coron-
ary heart disease; PAD, peripheral arterial dis-
ease; ASA, acetylsalicylic acid ; GFR, glomerular 
filtration rate ; § p<0.005 between group A and 
group B. # p<0.01 between controls and group 
A. ° p<0.0005 between controls and group B. 
Variable Group A 
N=84 
Group B 
N=66 
Controls 
N=60 
Age (years) * § #  48 (17–74) 52 (22–75) 52 (21–72) 
Males, n (%) 54 (64.3) 44 (66.6) 41 (68.3) 
GFR, ml/min* 65 (24–168) 64 (24–152)  
Cardiovascular risk factors 
Hypertension, n (%)# ° 65 (77.3) 58 (87.9) 15 (25) 
Smoking habit, n (%) 2 (2.4) 1 (1.5) 5 (8.3) 
Hypercholesterolaemia, n (%)# ° 45 (53.6) 25 (37.9) 7 (11.7) 
Diabetes, n(%)§ ° 7(8.3) 17 (25.7) 1 (1.6) 
Haemoglobin (g/dl)* #° 13.3 (9.9–17.3) 13.3 (10.1–17.4) 14.1 (12.1–16.4) 
Haematocrit (%)*# 38.8 (29.8–54.5) 39.8 (30.8–54.7) 41.8 (35.7–45.6) 
Platelets (x103/μl)* 220 (147–475) 223 (139–449) 212 (154–317) 
Comorbidities 
Previous DVT, n (%)  8 (9.5) 4 (4.8)  
Neoplastic disease, n (%)  12 (14.2) 9 (13.6)  
CHD, n (%)§  0 (0) 10 (15.1)  
PAD, n (%)§ 0(0) 6 (9.0)  
Renal artery stenosis, n (%)  4 (4.8) 2 (3)  
Liver disease, n (%)  5 (5.9) 6 (9.1)  
Medications 
Statins, n (%)  27 (32.1) 19 (28.8)  
Antihypertensive agents, n (%)§ 48 (57.1) 54 (81.8)  
Cyclosporine, n (%) 68 (80.9) 58 (87.9)  
Mycophenolate, n(%) 47 (55.9) 42 (63.6)  
Corticosteroids, n (%) 79 (94) 59 (89.3)  
Tacrolimus, n (%) 10 (11.9) 8 (12.1)  
Everolimus, n (%) 14 (16.6) 8 (12.1)  
Sirolimus, n (%) 5 (5.9) 0 (0)  
Azathioprine, n (%) 4 (4.8) 4 (6.1)  
Erythropoietin, n (%) 7 (8.3) 7 (10.6)  
Laboratory parameters  
Leucocyte number (x103/μl)* # 7.6 (3.3–14.1) 7.0 (2.9–15.7) 6.5 (4.3–11.3) 
Red blood cells (x106/μl)* #° 4.38 (3.0–7.05) 4.37 (3.14–6.29) 4.91 (3.82–5.60)
808 Cesari et al. Platelet turn-over in renal transplant recipients patients
Thrombosis and Haemostasis 104.4/2010 © Schattauer 2010
number of diabetic patients or to the predominant effect of other 
cardiovascular risk factors in RTRs patients.  
In the whole patients populations and in particular in RTRs pa-
tients not on ASA treatment, we documented a high degree of en-
dothelial perturbation, showed by the increased levels of vWF, 
which can induce enhanced platelet adhesion to the subendothe-
lium, and consequently increased platelet activation and con-
sumption.  
RP are immature platelets with a greater mass and a greater pro-
thrombotic potential with respect to smaller platelets. Indeed, they 
aggregate more rapidly in response to collagen, have higher levels 
of intracellular thromboxane A2 as well as increased levels of pro-
coagulant surface protein like P-selectin and GpIIb/IIIa (31–33). 
Moreover, it has been recently demonstrated that RP are associated 
with diminished antiplatelet effects of ASA and increased aspirin 
resistance, possibly due to the increased reactivity and the presence 
of uninhibited cyclooxygenase (COX)-1 and COX-2 activity (34). 
With regard to this issue, we recently reported that a high rate of 
platelet turnover, as documented by the presence of RP, represents 
a new mechanism associated with enhanced platelet reactivity in 
high-risk CAD patients on dual antiplatelet therapy (14).  
Similarly, the high rate of platelet turnover in RTRs patients 
Figure 1: IPF, H-IPF and IPF# in RTRs patients not on ASA treatment (group A), on ASA treatment (group B) and in control subjects. * group A 
vs. controls: IPF p<0.0001: H-IPF p<0.0001; IPF# p<0.0001. ** group A vs. group B: IPF p=0.003; H-IPF p=0.006; IPF# p=0.017. *** group B vs. controls: 
IPF p=0.004; H-IPF p=0.092; IPF# p=0.17. 
 RTRs not on aspirin 
(group A) 
n=84 
RTRs on aspirin 
(group B) 
n=66 
Controls 
 
n=60 
Coll-PA*# (%) 86 (41–95) 64 (5–100) 75 (10–91) 
AA-PA*# (%) 88 (10–100) 17 (5–92) 80 (10–123) 
ADP2-PA*# (%) 82 (9–100) 64 (21–89) 67 (17–96) 
ADP10-PA*# (%) 88 (33–100) 80 (34–94) 74 (46–94)
Table 2: Differences on platelet aggre-
gation between RTRs patients not on ASA 
treatment (group A) and controls. *Values 
are expressed as median and range. # 
p<0.0001 group A vs. controls. RTRs, renal 
transplant recipients. 
documented in the present paper is independently associated with 
the risk of a collagen-mediated residual platelet reactivity, despite 
of ASA treatment. These results are in keeping with a recent obser-
vation of “aspirin resistance” documented in 40 RTRs patients with 
a percentage (27.5%) similar to our finding (33%) (11). 
The number of newly produced circulating platelets depends 
on the stimulation of the thrombopoietic capacity of bone marrow 
as well as on the platelet removal from the bloodstream through an 
activation-dependent mechanism that enhances platelet turnover. 
In RTRs patients both mechanisms can be evoked in determining 
the number of reticulated platelets. In particular, the use of medi-
cations such erythropoietin can promote a release of RP from the 
bone marrow (35, 36); however, in our patients population only a 
minor percentage received this drug, and at the multivariate model 
adjusted also for this confounding factor, the associations between 
RP, platelet reactivity and RPR remained significant.  
The presence of a “sticky” endothelium in RTRs patients has 
been documented in various previous studies, by reporting high 
levels of intercellular and vascular cell adhesion molecules, such as 
intercellular adhesion molecule-1 and vascular cell adhesion mol-
ecule-1, as well as augmented levels of thrombomodulin in RTRs 
patients (4, 7). Taken together, all these aspects reflect a status of 
endothelial injury and activation that can play a role in determin-
ing an enhanced platelet adhesion and activation, with a con-
sequent consumption of platelets and a compensatory production 
from the bone-marrow of larger reticulated platelets.  
Furthermore, RTRs patients showed increased levels of throm-
bospondin-1 (TSP1), with respect to a control population (37). 
TSP1 is abundantly present in platelet alpha-granules, from where 
it is released upon platelet activation by reinforcing and stabilising 
platelet aggregates (38). TSP1, locally released by platelets, com-
petes also with ADAMTS13 during VWF proteolysis and controls 
the degree of VWF multimer processing (39). The higher levels of 
TSP1 can inhibit the activity of ADAMTS13 and determine higher 
levels of VWF by supporting the platelet hyper-function.  
On the other hand, some cytokines are able to augment mega-
karyopoiesis quantitatively (40) and in RTRs higher levels of tu-
mour necrosis factor-α, a cytokine which can act in promoting 
commitment along the megakaryocytic lineage leading to in-
creased thrombopoiesis, have been reported (4). 
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 Univariate Multivariate* 
β ± SE P β ± SE P 
LogIPF and LogColl-PA 0.34 ± 0.079 <0.0001 0.22 ± 0.074 0.003 
LogH-IPF and LogColl-PA 0.19 ± 0.069 0.007 0.17 ± 0.11 0.145 
LogIPF# and LogColl-PA 0.27 ± 0.070 <0.0001  0.20 ± 0.067 0.008
Table 3: Univariate and multivariate linear regression analysis between reticulated platelets (IPF; H-IPF and IPF#) and collagen-induced pla-
telet aggregation (Coll-PA). *Adjusted for age, gender, hypertension, dyslipidaemia, diabetes, smoking habit, haematocrit, ASA, cyclosporine and erythro-
poietin treatment, and glomerular filtration rate (GFR). 
 Without RPR by  
collagen 
n=27 
With RPR by 
collagen 
n=39 
P Without RPR 
by AA 
n=44 
With RPR by 
AA 
n=22 
P 
IPF (%) 2.9 (0.9–6.2) 3.9 (1.8–7.5)  0.009 3.5 (0.9–6.3) 3.3 (1.0–7.5)  0.88 
IPF# Platelets/μl  5600 
(1700–10600) 
7300  
(3100–15200) 
0.03 7150 
(2100–11100) 
6500 
(1700–15200) 
0.62 
H-IPF (%) 0.8 (0.2–1.9) 1.0 (0.3–2.5)  0.12 1.0 (0.3–2.5) 0.8(0.2–2.2)  0.30
Table 4: Differences in IPF, H-IPF and IPF# 
according to RPR.
What is known about this topic? 
● Renal transplant recipients (RTRs) patients are at increased risk of 
cardiovascular morbidity and mortality. 
● Epidemiological studies demonstrated that low-dose aspirin ther-
apy can improve renal allograft function and survival so reducing 
the incidence of cardiovascular complications in RTRs patients. 
● Scarce data are available about the platelet function reactivity in 
RTRs patients, and no data are present about the possible role of 
reticulated platelets (RP).  
What does this paper add? 
● We demonstrated a high platelet turnover in RTRs patients and an 
increased platelet reactivity in RTRs patients not on anti-aggregat-
ing therapy.  
● RTRs patients not on aspirin therapy showed significantly higher 
levels of von Willebrand factor (vWF) with respect to RTRs patients 
on aspirin therapy. 
● A positive relationship was observed between RP, platelet aggre-
gation by arachidonic acid and collagen and vWF levels. 
● The presence of elevated percentage of RP could be an additional 
mechanism involved in the increased cardiovascular risk profile of 
RTRs patients.
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Study limitations 
Some limitations of our study have to be acknowledged. First, the 
number of patients investigated is limited. Moreover it remains to 
be elucidated whether reticulated platelets represent the effect of 
increased consumption of over stimulated platelets, or the mech-
anism of platelet hyper-function. Finally, the lack of a follow-up 
period does not allow us to obtain data on the long-term outcomes 
and to establish if IPF values could have a role in the cardiovascu-
lar prognosis of RTRs patients. 
However, this is the first report which investigated reticulated 
platelets in relation to platelet reactivity in the clinical setting of 
RTRs patients, so documenting an enhanced platelet turnover as-
sociated with increased vWF and platelet function. 
The presence of elevated percentage of reticulated platelets 
could be an additional mechanism involved in the increased car-
diovascular risk profile of RTRs patients. If future studies perform-
ed in the same clinical setting confirm our data, antiplatelet pro-
phylaxis should be more widely used as a useful tool in reducing 
the risk of cardiovascular complications in RTRs patients. 
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